[Decreased count of small lymphocytes in the blood of patients with malignant bone tumors].

Blood small lymphocyte (not exceeding 7.5 micron in diameter) counts obtained from patients with malignant bone tumors in the course of primary examination were 40-75% those in healthy subjects. The said changes were registered only in some patients with osteoblastoclastoma; they were not observed in cases of trauma, osteomyelitis, sepsis, spontaneous osteolysis and chronic synovitis.

[Comparative analysis of immune response indices in lung cancer].

In 43 patients with cancer of the lung, a number of immunologic indexes were evaluated including lymphocyte response to PHA, lymphokine production, serum immunoglobulin levels and the regulatory effect of sera and T-lymphocytes on lymphokine production. No significant deficiency in T- and B-lymphocytes was registered in patients with stage I-III cancer, nor any rise in TG cell level was in evidence. The response to PHA was low; however, the capacity to produce lymphokines in the presence of allogeneic or autologous tumor antigens was unimpaired.

[Comparative analysis of immunoreactive indices in malignant and benign bone tumors].

The paper discusses the results of a study of immunologic surveillance in patients with bone tumors. T-lymphocyte deficiency was found in 21-32% of cases only, while all patients showed changes in the level of some T-cell subpopulations and their ratio. Patients with malignant tumors (mostly osteosarcoma) revealed a lowered response to PHA and a high frequency of sensitization to tumor antigens.

[Lymphocyte subpopulations in malignant bone tumors and their relation to the immune response to the tumor].

Comparative studies of the subpopulations of lymphocytes, isolated from the tumor tissue and blood of 15 osteosarcoma patients, showed that the total lymphocyte count in the neoplasms ranged from 0 to 19% of the total cell population. In various patients tumor lymphocytes were represented either mainly by T cells (up to 80% of lymphocytes) or by "null" cells lacking any surface markers. The population of lymphocytes with surface membrane immunoglobulins with complement and Fc receptors was usually low although the tumors contained up to 90% of nonlymphoid cells with the same markers.

[Detection of suppressor lymphocytes in the blood of oncological patients by using a 3-component lymphocyte mixed culture].

A 3 component mixed lymphocyte culture was used to identify the suppressor cell activity of lymphocytes in the blood of patients suffering from osteogenic sarcoma, osteoblastoclastoma and lung tumor. The lymphocytes of these patients suppressed the blastogenic reaction of lymphocytes from two unrelated donors. The suppressive activity of the lymphocytes form the patients with bone sarcoma was the strongest.

[In vitro immune response of patient lymphocytes to live autologous tumor cells].

In 87% of patients with malignant tumors and in 24% of patients with benign tumors there was found the in vitro immune response of lymphocytes to autologous tumor cells. Most of the autologous sera influenced the immune lymphocytes: those of malignant tumor patients usually blocked while those of benign tumor patients stimulated the immune reaction. Both the blocking and stimulating serum activities could be removed by absorption of the sera with living autologous tumor cells.

[Leukocyte adhesion suppression reaction for determining the immunological reactivity of oncological patients].

By means of the reaction of inhibition of leucocytes adhesiveness, suggested by Halliday and his coworkers, the authors examined the immune reactivity of 52 oncological patients and 25 healthy donors. The specific cell activity was observed only in oncological patients, and mainly against the antigen from autologous or histologically identical tumor. In a third of patients under examination blood serum would block the specific cell activity.

[Indices of cellular and humoral immunity following surgery intervention for malignant bone tumors].

The immunity indices were studied in 35 patients, operated upon for various types of osteosarcomas, as well as the nonspecific reactivity of T-and B-lymphocytes and the specific immune response of lymphocytes. The system of peripheral T-lymphocytes in these patients is being inhibited with the primary tumor progression and an unfavourable postoperative course. In a continuous (from 1 to 15 years) favourable course of the disease postoperatively a persistent restoration of T-lymphocytes reactivity was noted.

[Immunological study in carcinogenesis. Distribution of tissue incompatibility antigens (system HL-A) in oncological patients].

By means of a micromethod of lymphocytotoxic test the content of eleven HL-A antigens (1, 2, 3, 5, 7, 8, 9, 10, 11, 12 and 13) was studied in 200 healthy human subjects, 100 patients with rheumatoid polyarthritis and 82 patients with bone tumors. The latter included 50 patients with benign tumors (osteoblastoclastomas, chondroblastomas, chondromas, non-osteogenic fibromas) and 32 patients with malignant tumors (chondro- and osteosarcomas, Ewing sarcoma, malignant osteoblastoclastomas). It was found that in patients with different bone tumors antigen HL-7 was encountered reliably more frequently than in control groups, in patients with malignant tumor also antigen HL-A10 was more often detected.